Month: July 2014

Back to Basics: Unusual cases alter accuracy of IOL power calculations

For average eyes, IOL power estimation calculations are reasonably accurate because the assumptions that are made by the formulae all hold true: The anterior chamber is an average depth, the corneal curvature and axial length are accurately measured by our machines, and the future position of the IOL is accurately predicted. However, there are some clinical situations in which the IOL calculation is not as accurate, and we can end up with a refractive surprise.The surgeon should be aware of a patient’s history, review the biometric information in detail and (Read more...)

PK, DSAEK offer similar graft survival rates regardless of glaucoma therapy

Penetrating keratoplasty and Descemet’s stripping automated endothelial keratoplasty had comparable graft survival rates in eyes without glaucoma management and in eyes with comparable glaucoma management, according to a study.Researchers performed a retrospective chart review for 57 eyes that underwent PK and 156 eyes that underwent DSAEK. Patients’ eyes were categorized as having no glaucoma treatment, medical therapy only or surgical intervention.

New Eye Monitoring Device Spots Early Signs of Diabetes

Autonomic neuropathy is a common complication arising from diabetes, causing side effects like gastroparesis, erectile dysfunction, and other conditions due to damaged autonomic nerves. Early detection of diabetic autonomic neuropathy can have substantial benefits to patients thanks to treatment commencing sooner than it does now. Now researc (Read more...)

Ophthalmic Premier League Symposium offers friendly competition among surgeons

The Ophthalmic Premier League Symposium, a team video competition, will be debuted at the 2014 American Academy of Ophthalmology. “The video format makes this symposium very interesting for ophthalmologists, and added to it is the competition element where the ophthalmologists in the audience can vote and decide the best team,” Agar Agarwal, MD, told Ocular Surgery News in an interview.

Ten-point scorecard can assess administrator prowess

In today’s complex and changing practice world, few factors are as critical to practice success as your administrator’s global fitness. OSN Practice Management Board Member and Healio.com/Ophthalmology blogger Corinne Z. Wohl, MHSA, COE, an experienced hospital and practice administrator, provide insight into how the success of your administrator has a direct effect on the success of your practice.What follows is a simple “administrator’s scorecard.” It will help you answer one of the most common questions asked of practice management consultants: “How is my manager doing?”

Ocular Therapeutix prices initial public offering at $13 per share

Ocular Therapeutix has priced its initial public offering of 5,000,000 common stock shares at $13 per share, before underwriting discounts and commissions, according to a company press release.The company has also granted the underwriters an option for a 30-day purchase period at the public offering price excluding the underwriting discount — up to 750,000 additional shares of common stock to cover over-allotments, according to the press release.

European authorities recommend marketing extension for Ozurdex

The European Union’s Committee for Medicinal Products for Human Use has recommended extending the marketing authorization for the dexamethasone 700 mcg intravitreal implant in applicator, according to an Allergan press release.Dexamethasone 700 mcg intravitreal implant (Ozurdex, Allergan) is indicated for adult patients with vision loss due to diabetic macular edema who are pseudophakic, or who are unable to undergo non-corticosteroid therapy.